External subretinal drainage, bevacizumab, and scleral buckling for complete exudative retinal detachment after photocoagulation in retinopathy of prematurity.
BACKGROUND
Total serous retinal detachment after laser photocoagulation for retinopathy of prematurity is an infrequent type of retinal detachment in preterm babies.


OBJECTIVE
To describe the successful outcome for treatment by scleral drainage, bevacizumab, and scleral buckling for complete serous exudative retinal detachment in a patient with retinopathy of prematurity.


METHODS
A preterm baby with primary pulmonary hypertension under treatment with sildenafil developed a total (retrolental) serous retinal detachment after photocoagulation for threshold retinopathy. The dense subretinal fluid was externally drained using a bent needle with an infusion placed in the anterior chamber. Additional bevacizumab and scleral buckling helped to control the plus disease and subretinal leakage.


RESULTS
Retinal apposition was obtained with the described approach.


CONCLUSIONS
Total serous retinal detachment is a rare but severe visual complication in retinopathy of prematurity. The described technique may restore the retinae immediately in a visually critical period.
*Department of Ophthalmology, Hospital Universitario La Paz, Madrid, Spain; and †Department of Ophthalmology, Istituto Clinico Humanitas, Rozzano, Milan, Italy.
Felix
F
Armada-Maresca
Jesus
J
Peralta-Calvo
Natalia
N
Pastora-Salvador
Anna
A
Grabowska
Jose
J
Vallejo-Garcia
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D004322:Drainage / Q000379:methods; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D017075:Laser Coagulation / Q000009:adverse effects*; D054023:Lasers, Semiconductor / Q000009:adverse effects*; D008297:Male; D012163:Retinal Detachment / Q000209:etiology / Q000628:therapy*; D012178:Retinopathy of Prematurity / Q000601:surgery*; D012591:Scleral Buckling / Q000379:methods*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab